Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.
Akache B, Renner TM, Stuible M, Rohani N, Cepero-Donates Y, Deschatelets L, Dudani R, Harrison BA, Gervais C, Hill JJ, Hemraz UD, Lam E, Régnier S, Lenferink AEG, Durocher Y, McCluskie MJ.
Akache B, et al.
NPJ Vaccines. 2022 Oct 12;7(1):118. doi: 10.1038/s41541-022-00540-7.
NPJ Vaccines. 2022.
PMID: 36224247
Free PMC article.
This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants....
This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in …